Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 1, 2018 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 1, 2018 Category: Nuclear Medicine Source Type: research
Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155
Sepantronium bromide (YM155) is a survivin suppressant that induces apoptosis in tumor cells. Although YM155 induces tumor regression in various tumor types in vivo, phase I and II studies demonstrated responding and non-responding patient populations. We investigated 11C-labeled YM155 ([11C]YM155) used as a positron emission tomography (PET) tracer to assess whether tumor uptake of [11C]YM155 correlated with its anti-tumor effect, thereby allowing identification of patients who would respond to YM155 treatment. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 26, 2018 Category: Nuclear Medicine Authors: Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, Kenna Shirasuna, Akihiro Noda, Kentaro Yamanaka, Naoki Kaneko, Sosuke Miyoshi Source Type: research
Semi-automated system for concentrating 68Ga-eluate to obtain high molar and volume concentration of 68Ga-Radiopharmaca for preclinical applications
68Ga-radiopharmaceuticals are common in the field of Nuclear Medicine to visualize receptor-mediated processes. In contrast to straightforward labeling procedures for clinical applications, preclinical in vitro and in vivo applications are hampered for reasons like e.g. volume restriction, activity concentration, molar activity and osmolality. Therefore, we developed a semi-automatic system specifically to overcome these problems. A difficulty appeared unexpectedly, as intrinsic trace metals derived from eluate (Zn, Fe and Cu) are concentrated as well in amounts that influence radiochemical yield and thus lower molar activ...
Source: Nuclear Medicine and Biology - June 26, 2018 Category: Nuclear Medicine Authors: Erik de Blois, Rory M.S. de Zanger, Elisabeth Oehlke, Ho Sze Chan, Wouter A.P. Breeman Source Type: research
Evaluation of a chloride-based 89Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin
The remarkable stability of the 89Zr-DOTA complex has been shown in recent literature. The formation of this complex appears to require 89Zr-chloride as the complexation precursor rather than the more conventional 89Zr-oxalate. In this work we present a method for the direct isolation of 89Zr-chloride from irradiated natY foils. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 17, 2018 Category: Nuclear Medicine Authors: Stephen A. Graves, Christopher Kutyreff, Kendall E. Barrett, Reinier Hernandez, Paul A. Ellison, Steffen Happel, Eduardo Aluicio-Sarduy, Todd E. Barnhart, Robert J. Nickles, Jonathan W. Engle Source Type: research
Establishment of a method for in-vivo SPECT/CT imaging analysis of 111In-labeled exendin-4 pancreatic uptake in mice without the need for nephrectomy or a secondary probe
In this study, we aimed to establish an analytical method for murine in-vivo SPECT/CT imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 8, 2018 Category: Nuclear Medicine Authors: Keita Hamamatsu, Hiroyuki Fujimoto, Naotaka Fujita, Takaaki Murakami, Hiroyuki Kimura, Hideo Saji, Nobuya Inagaki Source Type: research
Matched-pair, 86Y/90Y-labeled, Bivalent RGD/Bombesin Antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a Potential Theranostic Agent for Prostate Cancer
In this study, we describe development of a true matched-pair theranostic agent that is able to target the αVβ3 integrin and the gastrin releasing peptide receptor (GRPR). We herein describe methods to metallate and characterize the new conjugate and to validate its biological efficacy by in vitro and in vivo methods. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 8, 2018 Category: Nuclear Medicine Authors: Nilantha Bandara, Tamila J. Stott Reynolds, Rebecca Schehr, Rajendra P. Bandari, Philipp J. Diebolder, Stephanie Krieger, Jingli Xu, Yubin Miao, Buck E. Rogers, Charles J. Smith Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 1, 2018 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 1, 2018 Category: Nuclear Medicine Source Type: research
99mTc labeled D(LPR): A novel retro-inverso peptide for VEGF receptor-1 targeted tumor imaging
The aim of this study was to evaluate the ability of D(LPR), a novel retro-inverso peptidomimetic derivative for imaging colon cancer. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 31, 2018 Category: Nuclear Medicine Authors: Farzaneh Rezazadeh, Nourollah Sadeghzadeh, Seyed Mohammad Abedi, Saeid Abediankenari Source Type: research
99mTc-D(LPR): A novel retro-inverso peptide for VEGF receptor −1 targeted tumor imaging
The aim of this study was to evaluate the ability of D(LPR), a novel retro-inverso peptidomimetic derivative for imaging colon cancer. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 31, 2018 Category: Nuclear Medicine Authors: Farzaneh Rezazadeh, Nourollah Sadeghzadeh, Seyed Mohammad Abedi, Saeid Abediankenari Source Type: research
One-pot synthesis and biodistribution of fluorine-18 labeled serum albumin for vascular imaging
Equilibrium single-photon radionuclide imaging methods for assessing cardiac function and the integrity of the vascular system have long been in use for both clinical and research purposes. However, positron-emitting blood pool agents that could provide PET equivalents to these (and other) clinical procedures have not yet been adopted despite technical imaging advantages offered by PET. Our goal was to develop a PET blood pool tracer that not only meets necessary in vivo biological requirements but can be produced with an uncomplicated and rapid synthesis method which would facilitate clinical translation. (Source: Nuclear...
Source: Nuclear Medicine and Biology - May 30, 2018 Category: Nuclear Medicine Authors: Falguni Basuli, Xiang Zhang, Mark R. Williams, Jurgen Seidel, Michael V. Green, Peter L. Choyke, Rolf E. Swenson, Elaine M. Jagoda Source Type: research
One-Pot Synthesis and Bio-distribution of Fluorine-18 Labelled Serum Albumin for Vascular Imaging
Equilibrium single-photon radionuclide imaging methods for assessing cardiac function and the integrity of the vascular system have long been in use for both clinical and research purposes. However, positron-emitting blood pool agents that could provide PET equivalents to these (and other) clinical procedures have not yet been adopted despite technical imaging advantages offered by PET. Our goal was to develop a PET blood pool tracer that not only meets necessary in vivo biological requirements but can be produced with an uncomplicated and rapid synthesis method which would facilitate clinical translation. (Source: Nuclear...
Source: Nuclear Medicine and Biology - May 30, 2018 Category: Nuclear Medicine Authors: Falguni Basuli, Xiang Zhang, Mark R. Williams, Jurgen Seidel, Michael V. Green, Peter L. Choyke, Rolf E. Swenson, Elaine M. Jagoda Source Type: research
The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates
Radium-223 dichloride is the first alpha-particle emitting therapeutic agent approved by FDA and EMA for bone metastatic castration-resistant prostate cancer. We studied its age-dependent biodistribution in mice, and compared it with [99mTc]Tc-MDP and [18F]NaF aiming to identify a potential imaging surrogate to predict [223Ra]RaCl2 whole-body localization. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 8, 2018 Category: Nuclear Medicine Authors: Wen Jiang, David Ulmert, Brian W. Simons, Diane S. Abou, Daniel L.J. Thorek Source Type: research
Impact of structural alterations on the Radiopharmacological profile of 18F-labeled pyrimidines as Cyclooxygenase-2 (COX-2) imaging agents
Non-invasive imaging of COX-2 in cancer represents a powerful tool for assessing COX-2-mediated effects on chemoprevention and radiosensitization using potent and selective COX-2 inhibitors as an emerging class of anticancer drugs. Careful assessment of the pharmacokinetic profile of radiolabeled COX-2 inhibitors is of crucial importance for the development of suitable radiotracers for COX-2 imaging in vivo. The delicate balance between the selection of typical COX-2 pharmacophores and the resulting physicochemical characteristics of the COX-2 inhibitor represents a formidable challenge for the search of radiolabeled COX-2...
Source: Nuclear Medicine and Biology - May 5, 2018 Category: Nuclear Medicine Authors: Ole Tietz, Alison Marshall, Cody Bergman, Melinda Wuest, Frank Wuest Source Type: research
